X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New analysis: Government intervention in Part B threatens patient access to medicines

By Nicole Longo  |    August 19, 2019
A new analysis from Avalere looked at how access to medicines in Part B may be impacted if the government only covered a certain list of medicines, an approach known as applying a national...   Read More

Setting the record straight on international reference pricing

By Kevin Haninger  |    July 16, 2019
There’s been a lot of talk in Washington about how to help patients better access and afford their medicines. These are important discussions that will hopefully result in real affordability...   Read More

No matter how you structure it, government arbitration is wrong for Medicare drug coverage

By Nicole Longo  |    June 27, 2019
Despite concerns from a broad group of stakeholders, some in Washington continue to push for imposing government arbitration on Medicare drug coverage to set the price of a medicine....   Read More

What you should know: Government arbitration is the wrong way to change Medicare

By Juliet Johnson  |    June 10, 2019
As Washington looks to make changes to Medicare, there are right ways and wrong ways to address the challenges patients face. In recent weeks, policymakers have discussed imposing government...   Read More

By the numbers: A look at the Part B International Pricing Index Model

By Nicole Longo  |    June 6, 2019
Mounting research continues to point to how international reference pricing schemes, like the Department of Health and Human Services’ (HHS) International Pricing Index (IPI) Model, could result...   Read More

Event tomorrow: Improving access and affordability for America’s seniors

By Andrew Powaleny  |    May 7, 2019
Medicare Parts B and D have played an important role in providing seniors with access to the lifesaving treatments they need and have been successful in delivering value to both the health care...   Read More

Fact Check: How the Part B International Pricing Index Model replaces market competition with government-set prices

By Nicole Longo  |    May 3, 2019
One of the most common misconceptions about the administration’s proposed Part B International Pricing Index (IPI) Model is that it would improve competition in Medicare. However, mounting...   Read More

340B continues to drive shift in site of care for physician-administered medicines to more expensive hospital settings

By Nicole Longo  |    April 5, 2019
Is 340B benefiting the vulnerable, uninsured patients it was designed to help? Evidence continues to show otherwise. An updated analysis from Berkeley Research Group (BRG) is the latest to build...   Read More

Fact Check: How the Part B International Pricing Index model threatens patient access

By Nicole Longo  |    March 29, 2019
Since the Department of Health and Human Services (HHS) released the Part B International Pricing Index (IPI) model late last year, there have been a number of inaccurate claims floating around...   Read More

New analysis finds Average Sales Price system has led to significant cost savings for Medicare and seniors

By Nicole Longo  |    March 7, 2019
When Congress created the Medicare Part D program as part of the Medicare Modernization Act of 2003 (MMA), it also implemented changes to Part B to make it market based with the creation of the...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates